236 related articles for article (PubMed ID: 12692781)
1. Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1alpha,24-dihydroxyvitamin D2.
Bauer JA; Thompson TA; Church DR; Ariazi EA; Wilding G
Prostate; 2003 May; 55(3):159-67. PubMed ID: 12692781
[TBL] [Abstract][Full Text] [Related]
2. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides.
Eder IE; Culig Z; Ramoner R; Thurnher M; Putz T; Nessler-Menardi C; Tiefenthaler M; Bartsch G; Klocker H
Cancer Gene Ther; 2000 Jul; 7(7):997-1007. PubMed ID: 10917202
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
Hobisch A; Ramoner R; Fuchs D; Godoy-Tundidor S; Bartsch G; Klocker H; Culig Z
Clin Cancer Res; 2001 Sep; 7(9):2941-8. PubMed ID: 11555613
[TBL] [Abstract][Full Text] [Related]
6. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3.
Miller GJ; Stapleton GE; Ferrara JA; Lucia MS; Pfister S; Hedlund TE; Upadhya P
Cancer Res; 1992 Feb; 52(3):515-20. PubMed ID: 1370648
[TBL] [Abstract][Full Text] [Related]
7. Regulation of aromatase and 5alpha-reductase by 25-hydroxyvitamin D(3), 1alpha,25-dihydroxyvitamin D(3), dexamethasone and progesterone in prostate cancer cells.
Lou YR; Murtola T; Tuohimaa P
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):151-7. PubMed ID: 15862960
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
Chiu FL; Lin JK
Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy.
Díaz GD; Paraskeva C; Thomas MG; Binderup L; Hague A
Cancer Res; 2000 Apr; 60(8):2304-12. PubMed ID: 10786699
[TBL] [Abstract][Full Text] [Related]
10. The novel analog 1,24(S)-dihydroxyvitamin D2 is as equipotent as 1,25-dihydroxyvitamin D3 in growth regulation of cancer cell lines.
Levy Y; Knutson JC; Bishop C; Shany S
Anticancer Res; 1998; 18(3A):1769-75. PubMed ID: 9673403
[TBL] [Abstract][Full Text] [Related]
11. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
[TBL] [Abstract][Full Text] [Related]
12. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays.
Krishnan AV; Shinghal R; Raghavachari N; Brooks JD; Peehl DM; Feldman D
Prostate; 2004 May; 59(3):243-51. PubMed ID: 15042599
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.
Gregory CW; Johnson RT; Mohler JL; French FS; Wilson EM
Cancer Res; 2001 Apr; 61(7):2892-8. PubMed ID: 11306464
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells.
Cronauer MV; Nessler-Menardi C; Klocker H; Maly K; Hobisch A; Bartsch G; Culig Z
Br J Cancer; 2000 Jan; 82(1):39-45. PubMed ID: 10638964
[TBL] [Abstract][Full Text] [Related]
15. Effect of calcitriol on prostate-specific antigen in vitro and in humans.
Beer TM; Garzotto M; Park B; Mori M; Myrthue A; Janeba N; Sauer D; Eilers K
Clin Cancer Res; 2006 May; 12(9):2812-6. PubMed ID: 16675575
[TBL] [Abstract][Full Text] [Related]
16. 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells.
Serda RE; Bisoffi M; Thompson TA; Ji M; Omdahl JL; Sillerud LO
Prostate; 2008 May; 68(7):773-83. PubMed ID: 18247401
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy for prostate cancer by targeting poly(ADP-ribose) polymerase.
Trofimova I; Dimtchev A; Jung M; Rosenthal D; Smulson M; Dritschilo A; Soldatenkov V
Cancer Res; 2002 Dec; 62(23):6879-83. PubMed ID: 12460902
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
Arnold JT; Le H; McFann KK; Blackman MR
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
[TBL] [Abstract][Full Text] [Related]
19. 1alpha,25-Dihydroxyvitamin D3-3beta-(2)-bromoacetate, an affinity labeling derivative of 1alpha,25-dihydroxyvitamin D3 displays strong antiproliferative and cytotoxic behavior in prostate cancer cells.
Swamy N; Persons KS; Chen TC; Ray R
J Cell Biochem; 2003 Aug; 89(5):909-16. PubMed ID: 12874825
[TBL] [Abstract][Full Text] [Related]
20. Androgen and taxol cause cell type-specific alterations of centrosome and DNA organization in androgen-responsive LNCaP and androgen-independent DU145 prostate cancer cells.
Schatten H; Ripple M; Balczon R; Weindruch R; Chakrabarti A; Taylor M; Hueser CN
J Cell Biochem; 2000 Jan; 76(3):463-77. PubMed ID: 10649443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]